Inactive Instrument

Highlights Oncorus, Inc.

Equities

ONCR

US68236R1032

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Oncorus, Inc. Enters into Lease Termination Agreement with IQHQ-4 Corporate, LLC	23-07-19	CI
Debt Limit Deal Approval, Jobs Data in Focus Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Friday	23-06-02	MT
Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
North American Morning Briefing : Caution -2-	23-05-10	DJ
ONCORUS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-24	AQ
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
Oncorus, Daewoong Pharmaceutical to Develop Lipid Nanoparticle Formulations for mRNA Drug Candidate; Shares Surge	23-01-04	MT
Oncorus, Inc. and Daewoong Pharmaceutical Co., Ltd. Announce Research Collaboration for Discovery and Development of Novel Lipid Nanoparticle Formulations for mRNA Drug Candidates	23-01-04	CI
Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer	22-11-30	CI
Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting	22-11-18	CI
ONCORUS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-02	AQ
Oncorus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer	22-10-07	CI
Oncorus, Inc. Enters into Second Amendment (Lease Amendment) to its Existing Lease with BMR-HAMPSHIRE LLC	22-09-14	CI
Oncorus : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)	22-08-04	PU
ONCORUS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-04	AQ
Oncorus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
ONCORUS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-04	AQ
Oncorus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting	22-04-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oncorus, Inc.

Equities

ONCR

US68236R1032

Highlights

Filters